Please assess the completion status of the following clinical trial:

Trial Title: The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a diagnosis of schizophrenia or schizoaffective disorder, as defined by DSM-IV-TR criteria and confirmed by the Structured Clinical Interview for DSM-IV (SCID)~* Duration of illness greater than 1 year, as defined by having initiated antipsychotic treatment at least 1 year prior to study entry~* Adequate decisional capacity to make a choice about participating in this research study~* Body mass index (BMI) at or greater than 27~* Currently being treated with one or a combination of two antipsychotic medications (typical or atypical) and on that drug regimen for at least 2 months prior to study entry, with stable dosages for at least 1 month~* If taking antidepressants, mood stabilizers, or anxiolytics, the dose must be stable for at least 1 month prior to study entry~* Willing to use an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study. Acceptable methods include oral, injectable, or implanted contraceptives; intrauterine devices or barrier methods such as condoms; and diaphragms and spermicides.~Exclusion Criteria:~* Inpatient status~* Clinical Global Impression Severity (CGI-S) score greater than 6~* Currently being treated with more than two antipsychotic medications~* Fasting glucose greater than 125~* Diagnosis of diabetes mellitus or treatment with insulin or oral hypoglycemics~* Previous or current treatment with metformin~* Diagnosis of congestive heart failure~* Renal impairment, as defined by a serum creatinine level greater than 1.5 in males or greater than 1.4 in females, or creatinine estimated glomerular filtration rate (GFR) outside of normal limits~* Hepatic disease, as defined by aspartate transaminase (AST), alanine transaminase (ALT), or c-glutamyl transferase (CGT) greater than 1.5 times upper limit of normal (ULN), or total bilirubin greater than 1.2 times ULN~* Metabolic acidosis, as defined by serum carbon dioxide less than the lower limit of normal~* Known hypersensitivity to metformin~* Pregnant or breastfeeding~* Recent (in the past 30 days) or scheduled radiological studies involving iodinated contrast material~* Alcohol abuse or dependence within the past month, as determined by the SCID~* Other serious and unstable medical condition in the judgment of the investigator~* Diagnosis of mental retardation, delirium, or dementia, as defined by DSM-IV-TR~* Failed to discontinue 4 weeks prior to study entry any medication used for weight loss~* Concurrent treatment with certain drugs that are known to increase metformin blood levels should be discussed with the Project Medical Officer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Encapsulated metformin 1000-2000 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules 2-4 daily

Based on this trial design, predict the completion outcome and termination type (if applicable).